Table 4 Logistic regression analysis of the risk factors for no-remission in the patients with pMN
From: Complement activation products in the circulation and urine of primary membranous nephropathy
Parameters | Univariate analysis | Multivariate analysis | ||
|---|---|---|---|---|
OR (95% CI) | P value | OR (95% CI) | P value | |
Gender (male) | 0.927 (0.390, 2.205) | 0.864 | Â | Â |
Age | 0.999 (0.968, 1.031) | 0.968 | Â | Â |
Nephrotic syndrome | 0.857 (0.364, 2.016) | 0.724 | Â | Â |
Anti-PLA2R antibody positivity | 0.375 (0.130, 1.082) | 0.070 | Â | Â |
Level of anti-PLA2R antibodies | 1.005 (1.001, 1.009) | 0.016 | 0.999 (0.992–1.006) | 0.773 |
Proteinuria | 1.117 (0.997, 1.251) | 0.056 | Â | Â |
Serum albumin | 0.918 (0.847, 0.996) | 0.040 | 0.893 (0.793–1.005) | 0.059 |
eGFR | 0.998 (0.987, 1.010) | 0.762 | Â | Â |
Serum-C3 | 0.092 (0.010, 0.880) | 0.038 | 0.967 (0.045–20.88) | 0.983 |
Serum-C4 | 0.195 (0.000, 271.8) | 0.658 | Â | Â |
P-C1q | 2.848 (0.710–11.422) | 0.140 |  |  |
P-C4d | 5.651 (0.046–687.1) | 0.480 |  |  |
P-MBL | 1.016 (0.992–1.040) | 0.191 |  |  |
P-Bb | 382.258 (0.0–1351.0) | 0.760 |  |  |
P-Properdin | 22.398 (0.071–7064) | 0.290 |  |  |
P-C3a | 1.001 (0.992–1.010) | 0.870 |  |  |
P-C5a | 1.013 (0.987–1.040) | 0.330 |  |  |
P-MAC | 0.671 (0.449–1.005) | 0.053 |  |  |
U-C1q | 1.063 (0.878–1.286) | 0.530 |  |  |
U-C4d | 1.086 (0.973–1.213) | 0.141 |  |  |
U-MBL | 1.700 (0.0–8,369,066.8) | 0.946 |  |  |
U-Bb | 0.890 (0.617–1.283) | 0.533 |  |  |
U-Properdin | 1.001 (0.993–1.009) | 0.824 |  |  |
U-C3a | 1.000 (0.998–1.003) | 0.731 |  |  |
U-C5a | 1.003 (0.994–1.012) | 0.530 |  |  |
U-MAC | 1.063 (0.938–1.206) | 0.338 |  |  |